Vaccination versus "wait and treat": how to subsidize them?
In this paper we discuss the application of different co-payment rates to alternative medical strategies. Two such strategies are considered: a "vaccination strategy", in which patients apply preventive measures before knowing if they have the disease, and a "wait and treat" strategy, in which patients are treated later only if they contract the disease. We show the second approach should be more generously subsidized by the regulator. This is, at least at first sight, a surprising result.